Your session is about to expire
← Back to Search
Other
Lu AG06466 for Multiple Sclerosis
Phase 1
Waitlist Available
Research Sponsored by H. Lundbeck A/S
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, week 5
Awards & highlights
Study Summary
This trial is testing a new drug to see if it can help reduce spasticity in people with MS.
Eligible Conditions
- Multiple Sclerosis
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline, week 5
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, week 5
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Change from Baseline to Week 5 in Spasticity NRS Score
Number of Participants with Spasticity Response
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Lu AG06466Experimental Treatment1 Intervention
Participants will receive Lu AG06466 at a starting dose orally once daily for 4 days (Day 1 to Day 4), followed by Lu AG06466 at a higher titrated dose orally once daily for 4 days (Day 5 to Day 8), followed by Lu AG06466 at a higher titrated treatment dose orally once daily from Day 9 until Day 35/Week 5.
Group II: PlaceboPlacebo Group1 Intervention
Participants will receive Lu AG06466-matching placebo orally once daily until Day 35/Week 5.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Lu AG06466
2020
Completed Phase 1
~90
Find a Location
Who is running the clinical trial?
H. Lundbeck A/SLead Sponsor
326 Previous Clinical Trials
77,646 Total Patients Enrolled
2 Trials studying Multiple Sclerosis
110 Patients Enrolled for Multiple Sclerosis
Email contact via H. Lundbeck A/SStudy DirectorLundbeckClinicalTrials@Lundbeck.com
188 Previous Clinical Trials
58,303 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger